Literature DB >> 7156888

Assessment of bone marrow and splenic erythropoiesis in myelofibrosis.

A Ferrant, J Rodhain, F Cauwe, M Cogneau, C Beckers, J L Michaux, R Verwilghen, G Sokal.   

Abstract

The iron uptake in bone marrow and spleen was measured in 29 patients with myelofibrosis using 52Fe and quantitative scanning. In 10 patients, no iron uptake in the marrow could be observed and active erythropoiesis was extramedullary only. In the bone marrow of patients with myelofibrosis, the iron uptake per nucleated red cell was less than that observed in conditions without myelofibrosis or extramedullary erythropoiesis. Increasing splenic iron uptake was likely to be associated with a decreasing bone marrow iron uptake and was related to the size of the spleen. The data suggest that in myelofibrosis, the spleen dominates iron uptake through intense erythropoiesis and a high splenic blood flow, thus restraining iron supply to the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7156888     DOI: 10.1111/j.1600-0609.1982.tb00611.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  3 in total

1.  Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.

Authors:  Thorsten Derlin; Haefaa Alchalby; Peter Bannas; Simon Veldhoen; Ivayla Apostolova; Ioanna Triviai; Frank M Bengel; Nicolaus Kröger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-20       Impact factor: 9.236

2.  Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

Authors:  G E Verhoef; C De Wolf-Peeters; A Ferrant; S Deprez; P Meeus; M Stul; P Zacheé; J J Cassiman; H Van den Berghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

3.  Clinical significance of microcytosis in patients with primary myelofibrosis.

Authors:  Paolo Strati; Naveen Pemmaraju; Zeev Estrov; Marylou Cardenas-Turanzas; Sherry Pierce; Kate J Newberry; Naval Daver; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-08-28       Impact factor: 3.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.